Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

mitoxantrone

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Topoisomerase II inhibitor

Related drugs:

‹

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

epirubicin (29)

daunorubicin (20)

cytarabine/daunorubicin liposomal formulation (19)

idarubicin hydrochloride (16)

dactinomycin (8)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

H-ferritin–nanocaged doxorubicin (0)

non-pegylated liposomal doxorubicin (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

doxorubicin liposomal (0)

›

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2	mitoxantrone Sensitive: A2 - Guideline mitoxantrone Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline ifosfamide + etoposide oral + mitoxantrone Sensitive : A2	ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline ifosfamide + etoposide oral + mitoxantrone Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2	vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive: A2 - Guideline vincristine + dexamethasone + mitoxantrone + pegaspargase Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2	cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive: A2 - Guideline cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar) Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline ifosfamide + etoposide oral + mitoxantrone Sensitive : A2	ifosfamide + etoposide oral + mitoxantrone Sensitive: A2 - Guideline ifosfamide + etoposide oral + mitoxantrone Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2	cytarabine + etoposide IV + mitoxantrone Sensitive: A2 - Guideline cytarabine + etoposide IV + mitoxantrone Sensitive : A2
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3
Chr del(5q)	Acute Myelogenous Leukemia	Chr del(5q)	Acute Myelogenous Leukemia	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3
KMT2A rearrangement	B Acute Lymphoblastic Leukemia	KMT2A rearrangement	B Acute Lymphoblastic Leukemia	bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive: C3 – Early Trials bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive : C3	bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive: C3 – Early Trials bortezomib + vorinostat + dexamethasone + mitoxantrone Sensitive : C3
COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor	COL6A3-CSF1 fusion	Tenosynovial Giant Cell Tumor	gefitinib + mitoxantrone Sensitive: C4 – Case Studies gefitinib + mitoxantrone Sensitive : C4	gefitinib + mitoxantrone Sensitive: C4 – Case Studies gefitinib + mitoxantrone Sensitive : C4
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	mitoxantrone Sensitive: D – Preclinical mitoxantrone Sensitive : D	mitoxantrone Sensitive: D – Preclinical mitoxantrone Sensitive : D
NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	NUP98-NSD1 fusion + FLT3-ITD mutation	Acute Myelogenous Leukemia	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D
ABCG2 overexpression	Solid Tumor	ABCG2 overexpression	Solid Tumor	mitoxantrone + TP-3654 Sensitive: D – Preclinical mitoxantrone + TP-3654 Sensitive : D	mitoxantrone + TP-3654 Sensitive: D – Preclinical mitoxantrone + TP-3654 Sensitive : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D
TOP2A amplification	Rectal Cancer	TOP2A amplification	Rectal Cancer	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D	mitoxantrone Resistant: D – Preclinical mitoxantrone Resistant : D